Evidence map›Paper›PMID 36172734›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2022

[Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs].

Yuanyuan Song, Ling Tang, Lin Xia, Xin Tong, Zhimin Yang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yuanyuan SongCenter for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Ling TangCenter for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Lin XiaCenter for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Xin TongCenter for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
Zhimin YangCenter for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
National Medical Products Administration · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The drugs of programmed cell death 1 and its ligand 1 immune checkpoint inhibitors have ushered in a new era of anti-tumor immunotherapy, which has shown outstanding efficacy in some tumors, such as Hodgkin lymphoma, but there is still low response rate in some kinds of tumors. In recent years, bispecific antibodies prepared by cell fusion, recombinant DNA, protein engineering and other technologies can specifically bind two antigens or epitopes at the same time or successively, play a synergistic role in tumor treatment, can effectively inhibit tumor immune escape, and improve the effect of anti-tumor treatment has become a hot spot in tumor research. This paper will summarize the clinical research and development of bispecific antibodies, to provide reference for the industry.
.

Indexed as

Antibodies, BispecificAntineoplastic AgentsLung NeoplasmsNeoplasmsDNA, RecombinantEpitopesHumansImmune Checkpoint InhibitorsImmunotherapyLigandsResearchAntibodies, BispecificAntineoplastic AgentsDNA, RecombinantEpitopesImmune Checkpoint InhibitorsLigandsBispecific antibodyClinical researchResearch progress

Identifiers

PMID36172734
PMCPMC9549423
OpenAlexW4298088362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.